NCT06837298 The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
| NCT ID | NCT06837298 |
| Status | Recruiting |
| Phase | — |
| Sponsor | PepsiCo Global R&D |
| Condition | Muscle Damage |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2025-02-07 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 76 participants in total. It began in 2025-02-07 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the effect of Vicia faba protein concentrate, a protein derived from Fava bean extract, on delayed onset muscle soreness (DOMS). Participants receive either 2.4g/day of PeptiStrong® supplement capsules or placebo capsules for 14 days until a strenuous exercise session. For the last 3 days, 2/3 of them stay on the same treatment and 1/3 of them switch from placebo to PeptiStrong®.
Eligibility Criteria
Inclusion Criteria: * Males and females 18 - 45 years of age. * Willing to fast overnight on the 4 testing occasions. * Participants agree to abstain from taking additional supplements throughout the testing period, with particular emphasis placed upon protein-based products (e.g., whey or casein based protein powders; animal derived protein hydrolysates; natural supplements constituted of vegetative protein hydrolysates from rice, fava bean, pea, carrot, spirulina, broccoli, potatoes; marine derived secondary metabolite products or protein hydrolysates including Omega-3 capsules or DHA). * Moderately active (exercise 3-5 days per week) * Fluent in reading, writing, and speaking English * Participants agree to maintain their normal diet and perform only light to moderate exercise for the duration of the study. * BMI between 18.5 and 29.9 kg/m2 * Participants agree to refrain from consuming alcohol in the 48 hours leading up to a test day. * Willingness to complete questionnaires, records and diaries associated with the study and to complete all lab visits. * Refrain from any exercise from 48 hours prior to each test or blood draw. * Healthy as determined by General Health Questionnaire. * Non-smoker Exclusion Criteria: * Individuals that are glucose-6-phosphate-dehydrogenase deficient. The test product in this study contains fava bean extract which may produce favism in genetically susceptible individuals. * Alcohol or drug abuse in the past year.3. Testosterone or estrogen supplementation (not including women on oral contraceptives) * Pregnant or nursing or planning to become pregnant. * Participation in any other clinical trial in the past 30 days. Participation in any PepsiCo trial in the past 6 months * Volunteers with unstable medical conditions. * Any complaints that could interfere with the ability to exercise. * Individuals who are cognitively impaired or unable to give informed consent. * Any co-morbidities interacting with mobility or muscle metabolism of the lower limbs (e.g. arthritis, spasticity / rigidity, all neurological disorders, paralysis). * Creatine supplements, corticosteroids, NSAIDS, amino acids, injectible peptides, collagen, and nicotinamide (Vit B3/niacin). * Presence or history of neurological disorders or significant psychiatric illness. * Any condition the study investigator believes would interfere with eligibility following the study protocol, effect the study results, or put the subject at undue risk. * Participation in resistance or aerobic exercise within 48 hours of the test days. * Participation of \>3 high-intensity exercise sessions per week. * Undertake recovery methods such as sea swims, foam rolling, cryotherapy or excessive stretching during days 14-17. * Have been in contact with a suspected or confirmed case of COVID-19 in previous 14 days. * Are Hepatitis A- or B-positive or have had a sexual partner infected with hepatitis or HIV and not taking medication. * Are not employed by, or have a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If you are unsure if a company would be considered a competitor to Gatorade, let the study investigator know the name of the other company and the nature of your relationship to that company before ou sign the informed consent
Contact & Investigator
Kris Osterberg, PhD, RD
PRINCIPAL INVESTIGATOR
PepsiCo R&D Life Sciences, Sports Science
Frequently Asked Questions
Who can join the NCT06837298 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Muscle Damage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06837298 currently recruiting?
Yes, NCT06837298 is actively recruiting participants. Contact the research team at kris.osterberg@pepsico.com for enrollment information.
Where is the NCT06837298 trial being conducted?
This trial is being conducted at Bradenton, United States.
Who is sponsoring the NCT06837298 clinical trial?
NCT06837298 is sponsored by PepsiCo Global R&D. The principal investigator is Kris Osterberg, PhD, RD at PepsiCo R&D Life Sciences, Sports Science. The trial plans to enroll 76 participants.